Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cisplatin + Paclitaxel + Toripalimab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cisplatin||Platinol||CDDP||Chemotherapy - Platinum 6||Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Toripalimab||JS001|JS-001|TAB001||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 63||Toripalimab (JS001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (PMID: 28317872; PMID: 32277740, PMID: 32406293).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||esophagus squamous cell carcinoma||not applicable||Cisplatin + Paclitaxel + Toripalimab||Phase II||Actionable||In a Phase II trial, Toripalimab (JS001) in combination with Taxol (paclitaxel) and Platinol (cisplatin) resulted in an objective response rate of 66.7% (8/12) and a disease control rate of 91.7% (11/12) in patients with metastatic esophageal squamous cell carcinoma, with a median duration of response of 6.8 months (J Clin Oncol 38: 2020 (suppl; abstr e15083); NCT02915432).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|